dipyridamole has been researched along with Protein Aggregation, Pathological in 1 studies
Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.
Protein Aggregation, Pathological: A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION; POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Höllerhage, M | 1 |
| Moebius, C | 1 |
| Melms, J | 1 |
| Chiu, WH | 1 |
| Goebel, JN | 1 |
| Chakroun, T | 1 |
| Koeglsperger, T | 1 |
| Oertel, WH | 1 |
| Rösler, TW | 1 |
| Bickle, M | 1 |
| Höglinger, GU | 1 |
1 other study available for dipyridamole and Protein Aggregation, Pathological
| Article | Year |
|---|---|
Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells.
Topics: alpha-Synuclein; Animals; Cell Line; Dipyridamole; Drug Discovery; Drug Evaluation, Preclinical; Enz | 2017 |